Humacyte, Inc. (HUMA)
(Delayed Data from NSDQ)
$6.42 USD
+0.94 (17.15%)
Updated May 14, 2024 04:00 PM ET
After-Market: $6.42 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Price, Consensus and EPS Surprise
HUMA 6.42 +0.94(17.15%)
Will HUMA be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for HUMA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for HUMA
Should You Buy Humacyte (HUMA) Ahead of Earnings?
Humacyte (HUMA) Up on HAV BLA Priority Tag for Vascular Trauma
HUMA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Affimed N.V. (AFMD) Reports Q2 Loss, Misses Revenue Estimates
Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q2 Loss, Tops Revenue Estimates
Humacyte, Inc. (HUMA) Reports Q1 Loss, Misses Revenue Estimates
Other News for HUMA
Humacyte extends gains as FDA reviews blood vessel product
Humacyte: A Strong Opportunity In Wound Healing - A 'Buy' Before Price Gets Too High
Analysts Are Bullish on Top Healthcare Stocks: Humacyte (HUMA), Rallybio (RLYB)
Humacyte to Participate at Upcoming Investor Conferences in May
Benchmark Co. Keeps Their Buy Rating on Humacyte (HUMA)